Oregon Health & Science University researchers have confirmed that the timing of COVID-19 vaccination is associated with slight, temporary changes in menstrual cycle length. The study, published today… read more.
Rice University researchers have developed a rapid, accurate test for diagnosing malaria that is significantly faster and easier to use than traditional tests. The advancement has the potential… read more.
The Vaccine Adverse Event Reporting System (VAERS) is an open, national surveillance system used by medical professionals as well as the public at large to self-report potential adverse… read more.
AIM ImmunoTech Inc. announced positive topline results from the Company’s Phase II study evaluating the efficacy and safety of Ampligen as a potential therapeutic for people with the… read more.
GSK plc announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted for review the regulatory application of Shingrix (Recombinant… read more.
In women living with HIV, preventive treatment with DHA-PPQ is a safe and effective strategy to prevent malaria during pregnancy, according to the final results of MAMAH, a clinical trial funded by the… read more.
Although most patients diagnosed with Covid-19 will quickly recover, some people experience symptoms that linger well after they start testing negative again — including insomnia. Scientists already knew… read more.
New research indicates that, among patients with Staphylococcus aureus (SAB) bloodstream infections who are deemed to be at low risk of developing infectious complications, an early switch to… read more.
An unprecedented resurgence in invasive meningococcal disease followed the lifting of pandemic restrictions in France, according to a paper published in the Journal of Infection and Public Health… read more.
ASHP Midyear Clinical Meeting – Highlights Antimicrobial resistance (AMR) caused an estimated five million deaths in 2019 and by 2050 this is likely to rise to 10 million… read more.
Theratechnologies Inc. announced that the FDA has approved the company’s Labelling Prior Approval Supplement to include a 2000-mg intravenous (IV) push loading dose for Trogarzo (ibalizumab-uiyk). IV push… read more.
Since the COVID-19 pandemic began, extensive research has emerged detailing the virus’s ability to attack multiple organ systems, potentially resulting in a set of enduring and often disabling… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
